Doctors at Stamford Therapeutics say cutting-edge new option significantly reduces severity and frequency of symptoms.
STAMFORD, CT – Heartburn, acid reflux, indigestion; most people will experience this feeling at some point in their lifetime. For those diagnosed with Gastroesophageal Reflux Disease (GERD), the experience is prolonged and far more severe.
A new potential treatment option being evaluated at a local clinical trial center may help change that.
“Many people with GERD often experience little to no relief of symptoms with current treatment options,” says Dr. David Radin, Principle Investigator at Stamford Therapeutics. “Our team is evaluating a new treatment, now in Phase 3 trials, that is showing promising results for those with persistent symptoms.”
The drug, a twice daily treatment, has shown to significantly reduce heartburn severity and also reduce the frequency of regurgitation, two of the most bothersome and frequent symptoms.
GERD is known to affect about 20 percent of the population in the U.S. and usually occurs when stomach acid or contents come back into the esophagus more than twice a week, due to weakened relaxed or weakened muscles at the bottom of the esophagus.
“Smoking, certain foods, pregnancy, obesity and a plethora of other factors all impact the development of GERD,” says Radin. “The constant irritation of acid in the esophagus, and potentially lungs, can have serious consequences if left untreated.”
GERD symptoms can lead to ulcers and narrowing of the esophagus as well as pre-cancerous tissue changes, all of which can be dangerous for a patient.
Stamford Therapeutics is continuing to recruit patients for this clinical trial and are offering compensation for participation. Participants also see a board-certified physician and have access to the investigational medication.
“Our team is committed to understanding this condition and helping those experiencing chronic symptoms find relief,” says Dr. Radin.
To learn more about this study and to find out how to get involved, call 203-325-8529 or visit stctrials.com
About Stamford Therapeutics
Since its founding 1994, the sole mission of Stamford Therapeutics Consortium (STC) has been to conduct the highest quality clinical trials so that new, safe and effective medications can be developed, researched and approved for a variety of indications and diseases. To learn more or to participate in a research study, visit stctrials.com